A team of Houston college students laced in the top 10 percent of 7,800 students at the National Cyber League competition. Photo courtesy of HCC

A team from Houston Community College had a strong showing earlier this month at the spring National Cyber League competition.

A team of HCC students placed in the top 10 percent of finishers, according to a statement from the college. More than 7,800 students from 450 universities and colleges across the U.S.competed in the semi-annual competition that tests participants’ skills in identifying hackers from forensic data, penetration testing, auditing vulnerable websites and recovering from ransomware attacks through a series of games.

“Our goal is to empower our students with the knowledge and tools they need to succeed as leaders in information technology, including the fast growing and in-demand areas of cyber security and artificial intelligence,” Dr. Madeline Burillo-Hopkins, president of HCC Southwest College and vice chancellor of workforce, says in a statement. “Again and again, we find that our students perform exceptionally well when compared to those from colleges and universities across the nation.”

Hira Ali, a participant and mother of two who served as vice president of the HCC Cyber Security Club before graduating this year, says the experience pushed her and her teammates to expand their knowledge outside of the classroom.

“It was a great experience for us,” she says in a statement. “It presented us, as teammates, with the opportunity to venture beyond our comfort zones and delve into unfamiliar concepts."

Ali added that she ate almost nothing and slept little for a week because she and her team were "totally immersed in the competition.” She plans to enroll in a four-year online degree program through Dakota State University.

According to Samir Saber, dean of HCC’s Digital, and Information Technology Center of Excellence, there are about 57,878 cyber jobs in Texas alone. HCC also shared that the median salary for security analysts in the Houston area is about $101,000, according to Lightcast, a labor market data analysis firm.

Earlier this month, HCC also announced that it would be rolling out a new innovation 60-hour degree program in the fall. The Smart Building Technology program will train students on the installation of low-voltage controls. Students will receive an Associate of Applied Science degree after completing the program, which is part of HCC Central’s Electrical Technology program in the Architectural Design and Construction Center of Excellence (COE).

In late 2022, HCC and partners also received a $1.8 million grant from JP Morgan Chase to launch a new certificate program to help residents who come from some of Houston’s most underserved and under-resourced neighborhoods find career opportunities in the clean energy, disaster response, utilities, trades and manufacturing fields. Partnering employers included The City of Houston, Harris County and TRIO Electric.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”